English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The prevalence of diabetes worldwide is continually increasing, and even more people are affected by prediabetes. As a result of scientific and economic growth, the number of diabetes patients has increased rapidly from less than 1% in the 1970s to more than 10% in the mid-1990s; in Korea, the incidence is projected to be 15% to 20% by 2030 [1]. Before 1996, only sulfonylureas and insulin were available for the treatment of type 2 diabetes mellitus (T2DM). Since then, drugs of several other classes have been developed.

What Is the Optimal Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients?: The Practical Evidence of Antidiabetic Monotherapy Study